The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.
Kent C. Shih
Research Funding - Celgene
Johanna C. Bendell
Research Funding - Celgene
Anne Reinert
Research Funding - Celgene
Suzanne Jones
Research Funding - Celgene
Robin Katie Kelley
Research Funding - Celgene
Jeffrey R. Infante
Research Funding - Celgene
Michael Korn
Research Funding - Celgene
Kristen Hege
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shuichan Xu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Lilly Wong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Yong Liu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Deborah Mortensen
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pamela N. Munster
Research Funding - Celgene